Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2015-08-24 Share Issue/Capital Cha…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Disclosure of the total number of voting rights and the number of shares of the share capital
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Disclosure of the total number of voting rights and the number of shares of the share capital' and provides specific figures for the number of shares and voting rights as of August 23rd, 2015. This type of mandatory disclosure, detailing the capital structure and voting power, is most closely related to announcements concerning share capital changes or voting rights. While it is not a formal vote result (DVA), it is a direct disclosure related to the underlying structure that determines voting rights. Given the options, this specific disclosure about the total number of voting rights and shares aligns best with the general category of capital structure updates or regulatory disclosures. Since it is a specific, periodic disclosure about the share capital and voting rights count, it fits the theme of 'Share Issue/Capital Change' (SHA) or potentially a general 'Regulatory Filing' (RNS). However, since it explicitly details the 'total number of voting rights' and 'number of shares', it is a direct update on the capital base. If a more specific category existed for 'Voting Rights Disclosure', that would be ideal. Comparing the provided definitions, 'SHA' (Share Issue/Capital Change) is the closest fit for a disclosure detailing the total number of shares and associated voting rights, as it pertains directly to the capital base. It is not an earnings release, management change, or audit report. Given the nature of the disclosure (total voting rights), it is a specific regulatory filing. I will classify it as SHA as it directly concerns the share capital count, which is a component of capital structure updates, although RNS is also plausible if SHA is interpreted too narrowly as only new issues/splits. Given the content focuses on the current count of shares and rights, SHA is the most relevant category among the choices that deal with the share structure.
2015-08-24 English
Quantum Genomics announces the appointment of Professor Faiez Zannad as its heart failure consultant
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Professor Faiez Zannad as a specialized consultant for Quantum Genomics to accelerate developments in heart failure treatment. This announcement concerns a change in senior personnel/advisors related to the company's operations and strategy, specifically in a medical/research capacity. This aligns best with the 'Board/Management Information' category, which covers changes in senior management or key advisory roles, even if the role is consultative rather than executive board membership. It is not a formal regulatory filing like 10-K, an earnings release, or a general regulatory announcement (RNS).
2015-07-27 English
Bilan semestriel du contrat de liquidité au 30 juin 2015
Regulatory Filings Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 30 juin 2015" (Semi-annual statement of the liquidity contract as of June 30, 2015). It details the holdings (cash and shares) within a liquidity contract managed by Invest Securities for Quantum Genomics, comparing the balance as of June 30, 2015, to the balance as of December 31, 2014, and noting a supplementary capital injection in February 2015. This type of disclosure, focusing on the status of a liquidity agreement, is a specific financial update related to market stability or capital management, but it does not fit neatly into the primary financial reports (10-K, IR) or standard corporate actions (DIV, SHA). Given the context of reporting on a specific financial arrangement (liquidity contract) and the semi-annual reporting period, it is most closely related to ongoing financial disclosures. Since there is no specific code for 'Liquidity Contract Status', and it is a formal, periodic financial update, it falls best under 'Interim / Quarterly Report' (IR) if it were a full financial report, but since it is highly specific and short, it is best classified as a general 'Regulatory Filing' (RNS) or potentially 'Capital/Financing Update' (CAP) due to the nature of the liquidity contract. However, liquidity contracts are often mandated disclosures related to market making or share stability, making RNS the most appropriate general regulatory fallback for specific, non-standard financial updates. Given the options, and recognizing this is a specific, periodic financial status report, RNS is the safest general classification, although it shares characteristics with CAP. I will select RNS as the best fit for a specific, non-standard regulatory disclosure.
2015-07-10 French
Quantum Genomics accélère ses développements dans le domaine de l'insuffisance cardiaque
Regulatory Filings Classification · 95% confidence The document is a press release from Quantum Genomics announcing a new research collaboration and clinical development plans for their heart failure program. It does not report financial results, dividends, or governance changes, nor is it a formal regulatory filing or a report publication announcement. It falls under general corporate news/regulatory announcements as it provides an update on company operations and strategic developments.
2015-07-02 French
Quantum Genomics speeds its development work in the field of heart failure
Regulatory Filings Classification · 90% confidence The document is titled 'Press release' and announces strategic business developments, specifically signing a research collaboration agreement and setting a goal for a Phase IIa clinical trial launch. It details operational updates, scientific progress (QGC101 drug candidate), and market context (heart failure statistics). This content structure—a formal announcement of operational or strategic news outside of mandatory periodic financial reporting (like 10-K or IR)—is characteristic of a general corporate announcement. Since there is no specific category for general operational press releases, and it is not a financial report, transcript, or management change, the most appropriate fallback category is Regulatory Filings (RNS), which often encompasses miscellaneous official company announcements not covered by more specific codes.
2015-07-02 French
Quantum Genomics obtient des résultats positifs avec l'étude menée dans l'insuffisance cardiaque chez le chien
Regulatory Filings Classification · 95% confidence The document is a 'Communiqué de presse' (Press Release) dated June 29, 2015, announcing positive study results regarding a treatment for heart failure in dogs. It details scientific findings, references previous research, and mentions a collaboration agreement with a major animal health company regarding future licensing and commercialization. This type of announcement, focusing on clinical/study results and partnership updates, is typically classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck. However, given the context of a press release announcing specific scientific progress and partnership milestones, and lacking the structure of a formal financial report (like 10-K, IR, or ER), the most appropriate general category for a non-standard, material announcement is Regulatory Filings (RNS). It is not a formal financial report, earnings release, or management discussion.
2015-06-29 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.